Long-term efficacy and safety of exemestane in the treatment of breast cancer.

34 There was a trend towards increased cardiovascular events (excluding hypertension and venous thromboembolism) following sequential treatment (tamoxifen followed by exemestane) as opposed to 5 years of tamoxifen alone, at 12.3% (n = 259) versus 10.4% (n = 211), which did not reach statistical significance but which the authors felt was important to acknowledge.

also in 111,027 other papers